Subscribe to stay informed!
Malvern-based PhaseBio Pharmaceuticals has signed an exclusive licensing agreement valued up to $245 million with Alfasigma of Italy, writes John George for the Philadelphia…
Last year, Malvern-based PhaseBio Pharmaceuticals went public and raised $46 million through an initial public stock offering, writes John George for the Philadelphia Business…
PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has been awarded a $2.8 million grant.
The Fast…
Malvern’s PhaseBio Pharmaceuticals has switched its focus from diabetes treatments to orphan diseases by closing a nearly $15 million round of financing to help…
PhaseBio Pharmaceuticals, Inc. of Malvern has closed a $40 million Series C financing round led by AstraZeneca.
The clinical-stage biopharmaceutical firm is focused on…
Before we send you to this site, please subscribe to our daily newsletter.